While no troops will be administering shots or dropping off doses, scores of Defense Department employees are involved in the effort.
Some trial participants only got a partial dose of AstraZeneca’s vaccine. Experts said the company’s spotty disclosures have eroded confidence.
The current lockdown is ending and a successful British vaccine could vanquish the virus by spring. But will that be enough to rebuild his sagging political fortunes?
AstraZeneca’s new clinical trial results are positive but confusing, leaving many experts wanting to see more data before passing final judgment on how well the vaccine will work.
In an early analysis, the drug maker zeroed in on a promising dosing plan for its vaccine.
The surge in coronavirus cases worldwide is helping researchers measure more quickly how well their vaccines protect against Covid-19.
Front-runners in the coronavirus vaccine race won’t make nearly as many doses this year as were predicted, but they may kick into high gear next year.
AstraZeneca and Johnson & Johnson have restarted their late-stage trials after finding that serious illnesses in a few volunteers appeared not to be related to the vaccines.
The drugmaker’s experimental antibody treatment is similar to the one President Trump received from Regeneron.
Big profits beckon for pharmaceutical companies, which are already using their work on vaccines to fight efforts in Washington to curb drug prices.
A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans.
The “cell lines” used to develop monoclonal antibodies, as well as remdesivir and vaccines, began with fetal tissue decades ago.
Despite slim chances that its vaccine will be ready by October, Pfizer has big incentives to hint that it might be.
We may not find out whether the vaccines prevent moderate or severe cases of Covid-19.
Developing an effective vaccine is the first step. Then comes the question of how to deliver hundreds of millions of doses that may need to be kept at arctic temperatures.
Despite the president’s repeated claims that a vaccine will be available in October, scientists, companies and federal officials all say that most people won’t get one until well into next year.
Researchers say drug companies need to be more open about how vaccine trials are run to reassure Americans who are skittish about getting a coronavirus vaccine.
The company said tests of its vaccine would start up again in Britain while remaining suspended in the U.S. and other countries. Pfizer, a competitor, announced an expansion of its trials.
A participant in the company’s late-stage coronavirus vaccine trial reportedly developed severe neurological symptoms. Now experts must assess whether the vaccine was responsible.
The statement is meant to reassure the public that the companies will not seek a premature approval of vaccines under pressure from the Trump administration.
The agency told public health agencies that two unidentified vaccines might be ready by October or November. We explain how vaccine trials work, when one might be ready, and who may get them first.
Widespread contagion, a deep bench of scientists and a robust vaccine-making infrastructure have made Brazil an important player in the quest to find a vaccine.
A new analysis shows how companies have funded political efforts that undermine their public stances.
Early trials showed a good immune response in vaccinated subjects, but one researcher sounded a note of caution: “There is still a long way to go.”
The Maryland-based company, which has never brought a product to market before, just made the biggest deal to date with the Trump administration’s Operation Warp Speed.
The White House is eager to project progress, but the public-private partnership it has created still faces scientific hurdles, internal tensions and questions from Congress.
The Trump administration announced a grant to AstraZeneca, which has licensed a potential vaccine that is in trials by Oxford University.
Facing a global scramble for materials, British officials bought millions of unproven kits from China in a gamble that became an embarrassment.